Rate this Article: Toxicity Assessment of Afatinib as Subsequent Line Therapy after Disease Progression On or After Platinum based Therapy in Recurrent, Unresectable, Locally Advanced or Metastatic HNSCC Patients - Retrospective Observational Study

Rating (1-10):

1

Comments (SR25710222651):

Please enter 100–200 characters. 0/200 characters

Full Name: Email Address (Important: You will receive Rating Verification Link on this Email Address):

Leave this field empty

Back to Article